Proteflazidum drops 30ml — Made in Ukraine — Free Delivery

PHARMACOLOGICAL PROPERTIES:

Pharmacodynamics. Flavonoid glycosides contained in wild cereals Deschampsia caespitosa L. and Calamagrostis epigeios L. inhibit virus-specific enzymes DNA polymerase, thymidine kinase and reverse transcriptase in virus-infected cells. This leads to a decrease or complete blocking of virus replication.

The effect of the preparation on influenza viruses of strains A, B consists in inhibiting neuraminidase activity, inducing the synthesis of endogenous interferon, inhibiting the synthesis of RNA of the virus.

At the same time, Proteflazid causes an increase in the production of endogenous alpha and gamma interferons to a physiologically active level, which increases the body's nonspecific resistance to viral and bacterial infections. Clinical studies have established that, under the condition of long-term daily intake of the preparation, the refractoriness of the immune system does not occur: there is no inhibition of the activity of alpha and gamma interferons, due to which the immune status of a person is normalized. This makes it possible to use the preparation over a long period for the treatment of recurrent chronic infections.

The preparation has antioxidant activity, since it prevents the accumulation of lipid peroxidation products and thereby inhibits the course of free radical processes. The preparation is a modulator of apoptosis, enhancing the action of apoptosis-inducing substances.

Pharmacokinetics. Has not been studied.

INDICATIONS:

The preparation is used:

• for the treatment of viral infections caused by the herpes simplex virus (Herpes simplex) type 1 and 2 (herpetic eczema, herpetic vesicular dermatitis, herpetic gingivostomatitis and pharyngotonsillitis, herpetic meningitis and encephalitis, herpetic eye diseases and genital herpes);
• for the treatment of herpes zoster (Herpes zoster);
• for the treatment of infections caused by the herpesvirus type 4 (Epstein-Barr virus) - acute and chronic active form;
• to treat an infection caused by the herpes simplex virus type 5 (cytomegalovirus);
• in the complex treatment of hepatitis B and C;
• for the complex treatment of viral, bacterial, fungal infections, their associations (chlamydia, mycoplasma, ureaplasma, etc.), including human papillomavirus infection;
• for the treatment and prevention of influenza and other acute respiratory viral infections;
• in the complex treatment of HIV infection and AIDS.

APPLICATION:

the preparation is dosed using a dropper. The required amount of the preparation should be dripped into water (1-2 tablespoons), taken 10-15 minutes before meals, and in the treatment of viral hepatitis - 1.5-2 hours after meals.

For the treatment of herpetic gingivostomatitis, pharyngotonsillitis; for the complex treatment of viral, bacterial, fungal infections and their associations, including human papillomavirus infection; to prevent viral and bacterial infections that occur in patients with insufficient immune system function, a basic dosage regimen is recommended for 1 month. If necessary, the period of taking the preparation is extended to 2 months without interruption (from the 4th week of admission - 12 drops 2 times a day). The duration of treatment for human papillomavirus infection is 3 months without interruption. A control study for papillomavirus should be carried out no earlier than 2 months after the end of treatment in order to prevent pseudo-positive results from being obtained.

The basic regimen for adults and children over the age of 12 years:

1st week - 7 drops, 2 times a day;

2-3 weeks - 15 drops, 2 times a day;

4th week - 12 drops, 2 times a day.

With a recurrent course of infections, as well as in frequently and long-term ill children, preparation treatment is carried out 2-4 times a year. Dosing is carried out according to the basic scheme and, accordingly, age doses.

The duration of treatment in pediatric practice is similar to that for adults, but comparable with age.For the treatment of herpetic eczema, herpetic vesicular dermatitis, herpetic meningitis and encephalitis, herpetic eye lesions, genital herpes; for the treatment of herpes zoster (herpes zoster); acute and chronic active form of Epstein-Barr viral infection, cytomegalovirus disease; complex treatment of opportunistic infections in HIV-infected and AIDS patients (before or after antiretroviral therapy), a treatment regimen for chronic, often recurrent herpes infection is recommended:

Adults and children over the age of 12:

7 drops 2 times a day for the next 3 days;

10 drops 2 times a day for the next 3 days;

12-15 drops 2 times a day for 3 months without interruption.

Supportive therapy after the main course of treatment should be carried out for 2-4 months, 10 drops 2 times a day.

In pediatric practice, the preparation is prescribed according to age doses.

In the treatment of herpes simplex infections of the skin and mucous membranes, acute forms of herpes zoster, papillomatosis of the skin, the solution should be applied to the damaged area up to 3-5 times a day.

To prepare the solution, dilute 1.5 ml (36–38 drops) in 10 ml of physiological sodium chloride solution.

For primary and recurrent genital herpes and papillomavirus infection, vaginal tampons are used with the preparation solution. To prepare the solution, it is necessary to dilute 3 ml (72-75 drops) of the preparation in 20 ml of physiological sodium chloride solution. The exposure time of vaginal tampons is 30–40 minutes; procedures should be performed 2 times a day. If a burning sensation occurs in the vagina, it is necessary to increase the amount of solvent.

External use should be carried out until signs of damage to the skin or mucous membranes disappear, but not less than 10 days.

In the treatment of viral hepatitis B, C for adults and children over the age of 12, the following dosage regimen is recommended:

from the 1st to the 3rd day - 4 drops 2 times a day;

from the 4th to the 6th day - 7 drops, 2 times a day;

from the 7th day - 15 drops, 2 times a day.

For the treatment of viral hepatitis in children under the age of 12, a children's dosage form of Proteflazid is used - Flavozid syrup.

Take the preparation 1.5-2 hours after meals. The duration of treatment is at least 6-12 months.

Treatment of viral hepatitis in HIV-infected and AIDS patients is carried out before or after antiretroviral therapy.Duration of taking the preparation for influenza and other acute respiratory viral infections:

for the purpose of treatment, the preparation is used for 2 weeks;

in case of bacterial complications, the duration of the preparation intake is 1 month;

for prophylactic purposes, the preparation is used for 2-3 weeks;

during an epidemic, taking the preparation can be extended up to 6 weeks.

CONTRAINDICATIONS:

hypersensitivity to the components of the preparation . Stomach or duodenal ulcer.

SIDE EFFECTS:

the use of the preparation, as a rule, does not cause side effects. There were isolated cases of gastrointestinal disorders - pain in the epigastric region, nausea, vomiting, diarrhea (if these symptoms are present, the preparation should be taken 1.5-2 hours after eating). A transient increase in body temperature up to 38 ° C is possible on the 3-10th day of preparation therapy.

Allergic reactions are rare, mainly in the form of an erythematous skin rash. In isolated cases, headache is possible. These phenomena disappeared after adjusting the dose and regimen of the preparation.

In the treatment of viral hepatitis in 10-15% of patients with severe cytolytic syndrome, an increase in the activity of aminotransferases (less often - the level of bilirubin) is noted.

In patients with chronic gastroduodenitis, an exacerbation of gastroduodenitis, the occurrence of gastroesophageal reflux (reflux esophagitis) is possible.

Sometimes there may be a headache, general weakness.

With local application of Proteflazid, a burning sensation, itching, dry skin may appear, which disappear after a decrease in the concentration of the preparation.

SPECIAL INSTRUCTIONS:

in the treatment of viral hepatitis in 10-15% of patients with severe cytolytic syndrome 3-4 weeks after the start of treatment, an increase in the activity of aminotransferases is noted, less often the level of bilirubin, which lasts for 2-4 weeks and does not require discontinuation of the preparation.

In patients with chronic gastroduodenitis in case of exacerbation of gastroduodenitis, in the event of gastroesophageal reflux, the preparation should be taken 1.5–2 hours after meals.

With a transient increase in body temperature to 38 ° C, it is necessary to temporarily, for 2-3 days, reduce the dose of Proteflazid by 2 times.

Use during pregnancy and lactation. During preclinical studies, teratogenic, mutagenic and carcinogenic effects were not revealed. Clinical experience of using the preparation in the II and III trimester of pregnancy and during lactation did not show a negative effect. However, it is necessary to adhere to the general rules for prescribing preparations during pregnancy and lactation, assessing the benefit / risk ratio.

Children. The use of Proteflazid in children is possible from birth.

The ability to influence the reaction rate when driving or working with other mechanisms. No negative impact on the performance of potentially hazardous activities requiring special attention and quick response has been identified.

INTERACTIONS:

during clinical use, the possibility and expediency of the combination of Proteflazid with antibiotics and antifungal preparations for the treatment of viral-bacterial and viral-fungal infections was established. Negative manifestations due to interactions with other preparations are unknown.

OVERDOSE:

cases have not been described, but side effects are possible, especially from the gastrointestinal tract. Treatment is symptomatic.

STORAGE CONDITIONS:

in a dark place at a temperature not exceeding 25 ° C. Do not freeze! Formation of a gel-like structure that breaks down on shaking is acceptable.